Glycemic and renal effects of SGLT2 Inhibitors in Prader-Willi syndrome: Benefits and risks

IF 4.7 2区医学 Q1 ENDOCRINOLOGY & METABOLISM

Diabetes & metabolism Pub Date : 2025-09-18 DOI:10.1016/j.diabet.2025.101704

Juliette Jacquot-Thierry , Sarah Chalopin , Héléna Mosbah , Émilie Montastier , Fabien Mourre , Blandine Gatta-Cherifi , Julien Bourry , Eléonore Guichard , Pauline Faucher , Christine Poitou , Chloé Amouyal

{"title":"Glycemic and renal effects of SGLT2 Inhibitors in Prader-Willi syndrome: Benefits and risks","authors":"Juliette Jacquot-Thierry , Sarah Chalopin , Héléna Mosbah , Émilie Montastier , Fabien Mourre , Blandine Gatta-Cherifi , Julien Bourry , Eléonore Guichard , Pauline Faucher , Christine Poitou , Chloé Amouyal","doi":"10.1016/j.diabet.2025.101704","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>Sodium-glucose cotransporter-2 inhibitors (SGLT2is) are widely used in type 2 diabetes (T2D) management, but their efficacy and tolerance in Prader-Willi syndrome (PWS) remains unknown. Given the early onset of diabetes and treatment challenges, evaluating SGLT2is in this population is essential.</div></div><div><h3>Research and methods</h3><div>In this retrospective, multicenter study, 48 adults with PWS and T2D, among whom 24 patients receiving SGLT2is, were followed over 6 months. Glycemic and renal parameters were analyzed at baseline and 6 months.</div></div><div><h3>Results</h3><div>HbA1c was higher in the SGLT2i group and significantly improved (<em>P</em> < 0.05) while it remained stable in controls. The albumin-to-creatinine ratio also decreased significantly<strong>.</strong> No significant weight change was noted. Adverse events occurred in 37.5 % of treated patients, including acute kidney injury in 8.3 %.</div></div><div><h3>Conclusions</h3><div>SGLT2is improve glycemic control and renal markers in PWS with no weight loss. Close safety monitoring is warranted, particularly regarding renal function in PWS and more generally towards all complex obesity with neurodevelopmental disorders.</div></div>","PeriodicalId":11334,"journal":{"name":"Diabetes & metabolism","volume":"51 6","pages":"Article 101704"},"PeriodicalIF":4.7000,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes & metabolism","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1262363625000989","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

Sodium-glucose cotransporter-2 inhibitors (SGLT2is) are widely used in type 2 diabetes (T2D) management, but their efficacy and tolerance in Prader-Willi syndrome (PWS) remains unknown. Given the early onset of diabetes and treatment challenges, evaluating SGLT2is in this population is essential.

Research and methods

In this retrospective, multicenter study, 48 adults with PWS and T2D, among whom 24 patients receiving SGLT2is, were followed over 6 months. Glycemic and renal parameters were analyzed at baseline and 6 months.

Results

HbA1c was higher in the SGLT2i group and significantly improved (P < 0.05) while it remained stable in controls. The albumin-to-creatinine ratio also decreased significantly. No significant weight change was noted. Adverse events occurred in 37.5 % of treated patients, including acute kidney injury in 8.3 %.

Conclusions

SGLT2is improve glycemic control and renal markers in PWS with no weight loss. Close safety monitoring is warranted, particularly regarding renal function in PWS and more generally towards all complex obesity with neurodevelopmental disorders.

查看原文本刊更多论文

SGLT2抑制剂对Prader-Willi综合征的血糖和肾脏影响：益处和风险

目的：钠-葡萄糖共转运蛋白-2抑制剂（SGLT2is）广泛用于2型糖尿病（T2D）治疗，但其在Prader-Willi综合征（PWS）中的疗效和耐受性尚不清楚。考虑到糖尿病的早期发病和治疗挑战，在这一人群中评估SGLT2is是必要的。研究与方法：在这项回顾性的多中心研究中，48例成人PWS合并T2D患者，其中24例接受SGLT2is，随访超过6个月。在基线和6个月时分析血糖和肾脏参数。结果：SGLT2i组HbA1c升高且显著改善（P < 0.05），而对照组保持稳定。白蛋白与肌酐比值也显著降低。没有发现明显的体重变化。不良事件发生率为37.5%，其中急性肾损伤发生率为8.3%。结论：SGLT2is改善了PWS患者的血糖控制和肾脏指标，但没有体重减轻。密切的安全监测是必要的，特别是关于PWS患者的肾功能，更普遍的是针对所有伴有神经发育障碍的复杂肥胖。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Diabetes & metabolism 医学-内分泌学与代谢

CiteScore

12.00

自引率

4.20%

发文量

审稿时长

13 days

期刊介绍： A high quality scientific journal with an international readership Official publication of the SFD, Diabetes & Metabolism, publishes high-quality papers by leading teams, forming a close link between hospital and research units. Diabetes & Metabolism is published in English language and is indexed in all major databases with its impact factor constantly progressing. Diabetes & Metabolism contains original articles, short reports and comprehensive reviews.